

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 140 COAGULATION (HEMAT.)						
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
080 FIBRINOGEN				CLIA TEST ID #: 825      EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-551	73    ACL 8 TO E	87    HEMOSIL-C		12	284.750	38.053	13.36	228.000	342.000	
2024-551	79    CS-2500	67    DADE		17	234.412	10.550	4.50	188.000	281.000	
2024-552	73    ACL 8 TO E	87    HEMOSIL-C		12	496.000	57.480	11.59	397.000	595.000	
2024-552	79    CS-2500	67    DADE		17	415.647	18.081	4.35	333.000	499.000	
2024-553	73    ACL 8 TO E	87    HEMOSIL-C		12	138.667	16.038	11.57	111.000	166.000	
2024-553	79    CS-2500	67    DADE		17	120.882	8.656	7.16	97.000	145.000	
2024-554	73    ACL 8 TO E	87    HEMOSIL-C		12	302.167	35.419	11.72	242.000	363.000	
2024-554	79    CS-2500	67    DADE		17	240.000	10.960	4.57	192.000	288.000	
2024-555	73    ACL 8 TO E	87    HEMOSIL-C		12	292.917	29.330	10.01	234.000	352.000	
2024-555	79    CS-2500	67    DADE		17	235.529	12.724	5.40	188.000	283.000	
081 PART.THROM. TIME-PTT				CLIA TEST ID #: 835      EVALUATION CRITERIA: TARGET VALUE 15 %						
2024-551	62    DADE SYS.	35    DADE ACTIN		62	38.859	1.629	4.19	33.000	44.700	
2024-551	69    DIAG.STAGO	49    STA-PTT		18	39.850	1.277	3.20	33.900	45.800	
2024-551	73    ACL 8 TO E	56    PTT-HEMO		34	37.968	0.751	1.98	32.300	43.700	
2024-551	76    STAGO STAR	49    STA-PTT		21	38.262	1.931	5.05	32.500	44.000	
2024-551	79    CS-2500	35    DADE ACTIN		17	39.712	1.867	4.70	33.800	45.700	
2024-552	62    DADE SYS.	35    DADE ACTIN		62	27.355	0.865	3.16	23.300	31.500	
2024-552	69    DIAG.STAGO	49    STA-PTT		18	28.411	0.716	2.52	24.100	32.700	
2024-552	73    ACL 8 TO E	56    PTT-HEMO		34	37.161	1.539	4.14	31.600	42.700	
2024-552	76    STAGO STAR	49    STA-PTT		21	28.267	0.774	2.74	24.000	32.500	
2024-552	79    CS-2500	35    DADE ACTIN		17	27.676	0.863	3.12	23.500	31.800	
2024-553	62    DADE SYS.	35    DADE ACTIN		62	28.600	0.955	3.34	24.300	32.900	

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 140 COAGULATION (HEMAT.)							
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024-553	69	DIAG.STAGO	49 STA-PTT	18	33.406	1.521	4.55	28.400	38.400		
2024-553	73	ACL 8 TO E	56 PTT-HEMO	34	29.365	0.442	1.50	25.000	33.800		
2024-553	76	STAGO STAR	49 STA-PTT	21	32.981	1.556	4.72	28.000	37.900		
2024-553	79	CS-2500	35 DADE ACTIN	17	29.365	0.800	2.72	25.000	33.800		
081	PART.THROM. TIME-PTT		CLIA TEST ID #: 835	EVALUATION CRITERIA: TARGET VALUE 15 %							
2024-554	62	DADE SYS.	35 DADE ACTIN	62	30.156	1.272	4.22	25.600	34.700		
2024-554	69	DIAG.STAGO	49 STA-PTT	18	30.917	1.508	4.88	26.300	35.600		
2024-554	73	ACL 8 TO E	56 PTT-HEMO	34	29.627	0.427	1.44	25.200	34.100		
2024-554	76	STAGO STAR	49 STA-PTT	21	29.375	0.954	3.25	25.000	33.800		
2024-554	79	CS-2500	35 DADE ACTIN	17	30.659	1.259	4.11	26.100	35.300		
2024-555	62	DADE SYS.	35 DADE ACTIN	62	43.308	1.853	4.28	36.800	49.800		
2024-555	69	DIAG.STAGO	49 STA-PTT	18	43.883	1.570	3.58	37.300	50.500		
2024-555	73	ACL 8 TO E	56 PTT-HEMO	34	44.694	1.220	2.73	38.000	51.400		
2024-555	76	STAGO STAR	49 STA-PTT	21	42.843	2.167	5.06	36.400	49.300		
2024-555	79	CS-2500	35 DADE ACTIN	17	44.129	2.080	4.71	37.500	50.700		
082	PROTHROMBIN TIME(PT)		CLIA TEST ID #: 845								
2024-551	62	DADE SYS.	33 DADE INNOV	58	19.275	0.703	3.65	16.400	22.200		
2024-551	73	ACL 8 TO E	41 HEMOSIL RE	30	22.740	0.838	3.68	19.300	26.200		
2024-551	76	STAGO STAR	44 STA NEO CI	14	26.286	1.398	5.32	22.300	30.200		
2024-551	79	CS-2500	33 DADE INNOV	18	19.411	0.287	1.48	16.500	22.300		
2024-552	62	DADE SYS.	33 DADE INNOV	58	11.188	0.364	3.26	9.500	12.900		
2024-552	73	ACL 8 TO E	41 HEMOSIL RE	30	11.107	0.213	1.92	9.400	12.800		
2024-552	76	STAGO STAR	44 STA NEO CI	14	13.679	0.399	2.91	11.600	15.700		
2024-552	79	CS-2500	33 DADE INNOV	18	11.567	0.186	1.60	9.800	13.300		
2024-553	62	DADE SYS.	33 DADE INNOV	58	12.277	0.375	3.05	10.400	14.100		
2024-553	73	ACL 8 TO E	41 HEMOSIL RE	30	13.897	0.390	2.81	11.800	16.000		
2024-553	76	STAGO STAR	44 STA NEO CI	14	15.157	0.518	3.42	12.900	17.400		

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL			GRP: 140 COAGULATION (HEMAT.)						
ANALYTE											
SAMPLE	METHOD	SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-553	79 CS-2500	33	DADE INNOV		18	12.872	0.119	0.93	10.900	14.800	
082	PROTHROMBIN TIME (PT)	CLIA TEST ID #: 845			EVALUATION CRITERIA: TARGET VALUE 15 %						
2024-554	62 DADE SYS.	33	DADE INNOV		58	10.229	0.312	3.05	8.700	11.800	
2024-554	73 ACL 8 TO E	41	HEMOSIL RE		30	11.317	0.303	2.68	9.600	13.000	
2024-554	76 STAGO STAR	44	STA NEO CI		14	12.750	0.241	1.89	10.800	14.700	
2024-554	79 CS-2500	33	DADE INNOV		18	10.800	0.075	0.69	9.200	12.400	
2024-555	62 DADE SYS.	33	DADE INNOV		58	26.009	1.057	4.06	22.100	29.900	
2024-555	73 ACL 8 TO E	41	HEMOSIL RE		30	32.593	1.371	4.21	27.700	37.500	
2024-555	76 STAGO STAR	44	STA NEO CI		14	35.043	1.909	5.45	29.800	40.300	
2024-555	79 CS-2500	33	DADE INNOV		18	26.306	0.545	2.07	22.400	30.300	

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPE: 20 HEMATOLOGY		SUB: 70 GENERAL			GRP: 100 HEMA. CELL IDENTIFI.						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
072 HEMA. CELL IDENTIFI.											
2024-501					007	007	029 - TOXIC GRAN	915	1	913	0
2024-501					007	007	006 - SEGMENTED	915	1	913	0
2024-501					007	007	007 - BASOPHIL,	915	913	913	100
2024-502					043	043	043 - ECHINOCYTE	915	908	908	100
2024-502					043	043	041 - ACANTHOCYT	915	7	908	0
2024-503					011	011	017 - MONOCYTE	915	1	913	0
2024-503					011	011	011 - HYPERSEGME	915	913	913	100
2024-503					011	011	061 - ROULEAUX	915	1	913	0
2024-504					017	017	029 - TOXIC GRAN	915	1	908	0
2024-504					017	017	011 - HYPERSEGME	915	1	908	0
2024-504					017	017	014 - LYMPHOCYTE	915	4	908	0
2024-504					017	017	017 - MONOCYTE	915	908	908	100
2024-504					017	017	001 - BLAST	915	1	908	0
2024-505					061	061	017 - MONOCYTE	915	1	913	0
2024-505					061	061	061 - ROULEAUX	915	913	913	100
2024-505					061	061	063 - BACTERIA	915	1	913	0

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 137 RETICULOCYTE COUNT						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
149	RETICULOCYTE COUNT	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {GREATER}							
2024-531	7	M.B.MANUAL		12	11.989	2.567	21.41	4.300	19.700	
2024-531	24	Unicel DxH		18	7.139	0.524	7.34	5.400	8.900	
2024-531	25	SYSMEX XN		31	3.319	1.513	45.58	0	7.900	
2024-532	7	M.B.MANUAL		12	5.911	1.790	30.28	0.500	11.300	
2024-532	24	Unicel DxH		18	3.289	0.409	12.45	2.100	4.500	
2024-532	25	SYSMEX XN		31	1.890	0.578	30.56	0.200	3.600	
2024-533	7	M.B.MANUAL		12	11.689	3.375	28.87	1.600	21.800	
2024-533	24	Unicel DxH		18	7.256	0.623	8.59	5.400	9.100	
2024-533	25	SYSMEX XN		31	3.303	1.487	45.00	0	7.800	
2024-534	7	M.B.MANUAL		12	1.356	0.469	34.62	0	2.800	
2024-534	24	Unicel DxH		18	0.733	0.129	17.60	0.300	1.100	
2024-534	25	SYSMEX XN		31	0.842	0.091	10.78	0.600	1.100	
2024-535	7	M.B.MANUAL		12	5.344	1.395	26.11	1.200	9.500	
2024-535	24	Unicel DxH		18	3.233	0.325	10.05	2.300	4.200	
2024-535	25	SYSMEX XN		31	1.923	0.590	30.66	0.200	3.700	

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 138 SED. RATE (ESR)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
153	SED. RATE (ESR)		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 35 % {GREATER}							
2024-541	4	SEDIPLAST		647	43.567	7.632	17.52	21.000	66.000	
2024-541	10	SEDI RATE		63	43.371	7.811	18.01	20.000	67.000	
2024-541	10	SEDI RATE		63	48.800	2.315	4.74	32.000	66.000	
2024-541	11	SEDIMAT-15		48	132.000	10.285	7.79	86.000	178.000	

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 138 SED. RATE (ESR)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-541	19	MINI CUBE		46	55.083	11.601	21.06	20.000	90.000	
153 SED. RATE (ESR)				CLIA TEST ID #: 0      EVALUATION CRITERIA: TARGET VALUE 3 SD OR 35 % {GREATER}						
2024-542	4	SEDIPLAST		647	6.895	1.864	27.03	1.000	12.000	
2024-542	10	SEDI RATE		63	7.600	1.744	22.94	2.000	13.000	
2024-542	10	SEDI RATE		63	8.143	1.562	19.18	3.000	13.000	
2024-542	11	SEDIMAT-15		48	8.511	5.648	66.35	0	25.000	
2024-542	19	MINI CUBE		46	15.500	2.944	18.99	7.000	24.000	
2024-543	4	SEDIPLAST		647	7.132	1.934	27.11	1.000	13.000	
2024-543	10	SEDI RATE		63	9.000	1.095	12.17	6.000	12.000	
2024-543	10	SEDI RATE		63	8.361	1.391	16.64	4.000	13.000	
2024-543	11	SEDIMAT-15		48	7.600	6.122	80.56	0	26.000	
2024-543	19	MINI CUBE		46	15.292	2.879	18.83	7.000	24.000	
2024-544	4	SEDIPLAST		647	43.493	7.513	17.27	21.000	66.000	
2024-544	10	SEDI RATE		63	43.016	7.237	16.82	21.000	65.000	
2024-544	10	SEDI RATE		63	47.400	9.604	20.26	19.000	76.000	
2024-544	11	SEDIMAT-15		48	127.318	16.742	13.15	77.000	178.000	
2024-544	19	MINI CUBE		46	56.458	16.902	29.94	6.000	107.000	
2024-545	4	SEDIPLAST		647	43.720	7.214	16.50	22.000	65.000	
2024-545	10	SEDI RATE		63	47.000	4.940	10.51	31.000	63.000	
2024-545	10	SEDI RATE		63	42.714	7.873	18.43	19.000	66.000	
2024-545	11	SEDIMAT-15		48	129.909	12.369	9.52	84.000	175.000	
2024-545	19	MINI CUBE		46	64.083	16.039	25.03	16.000	112.000	
SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 125 DIFF. FOR 5 PAR NEW						

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765	EVALUATION CRITERIA: TARGET VALUE	25	% OR 2.00	{GREATER}					
2024521x	1	SYSMEX CBC	1 NEUTROPHIL	25	XS SERIES	124	60.069	1.478	2.46	45.100	75.100
2024521x	1	SYSMEX CBC	2 LYMPHOCYTE	25	XS SERIES	124	13.688	1.389	10.14	10.300	17.100
2024521x	1	SYSMEX CBC	3 MONOCYTE	25	XS SERIES	124	0.879	0.260	29.62	0	2.900
2024521x	1	SYSMEX CBC	4 EOSINOPHIL	25	XS SERIES	124	15.866	0.431	2.72	11.900	19.800
2024521x	1	SYSMEX CBC	5 BASOPHIL	25	XS SERIES	124	9.340	0.899	9.62	7.000	11.700
2024521x	2	ACT PENTRA	1 NEUTROPHIL	15	COUL ACT 5	77	53.010	1.092	2.06	39.800	66.300
2024521x	2	ACT PENTRA	1 NEUTROPHIL	24	ABX PENTRA	29	51.493	1.236	2.40	38.600	64.400
2024521x	2	ACT PENTRA	2 LYMPHOCYTE	15	COUL ACT 5	77	42.292	0.987	2.33	31.700	52.900
2024521x	2	ACT PENTRA	2 LYMPHOCYTE	24	ABX PENTRA	29	40.831	1.182	2.89	30.600	51.000
2024521x	2	ACT PENTRA	3 MONOCYTE	15	COUL ACT 5	77	1.212	0.283	23.34	0	3.200
2024521x	2	ACT PENTRA	3 MONOCYTE	24	ABX PENTRA	29	1.324	0.208	15.70	0	3.300
2024521x	2	ACT PENTRA	4 EOSINOPHIL	15	COUL ACT 5	77	3.538	0.336	9.48	1.500	5.500
2024521x	2	ACT PENTRA	4 EOSINOPHIL	24	ABX PENTRA	29	3.486	0.233	6.68	1.500	5.500
2024521x	2	ACT PENTRA	5 BASOPHIL	15	COUL ACT 5	77	57.288	1.232	2.15	43.000	71.600
2024521x	2	ACT PENTRA	5 BASOPHIL	24	ABX PENTRA	29	2.893	0.069	2.39	0.900	4.900
2024521x	3	ADVIA 120	1 NEUTROPHIL	9	ADVIA-120	17	65.281	0.617	0.94	49.000	81.600
2024521x	3	ADVIA 120	2 LYMPHOCYTE	9	ADVIA-120	17	21.312	0.578	2.71	16.000	26.600
2024521x	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	17	8.329	0.538	6.46	6.200	10.400
2024521x	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	17	0.353	0.133	37.79	0	2.400
2024521x	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	17	0.724	0.323	44.60	0	2.700
2024521x	3	ADVIA 120	6 LUC	9	ADVIA-120	17	4.413	0.394	8.92	2.400	6.400
2024521x	4	AB- CELL-D	1 NEUTROPHIL	8	CELL-DYN	48	51.304	1.623	3.16	38.500	64.100
2024521x	4	AB- CELL-D	1 NEUTROPHIL	37	ABB.CEL RU	42	49.164	1.636	3.33	36.900	61.500
2024521x	4	AB- CELL-D	2 LYMPHOCYTE	8	CELL-DYN	48	37.715	1.789	4.74	28.300	47.100
2024521x	4	AB- CELL-D	2 LYMPHOCYTE	37	ABB.CEL RU	42	40.264	2.142	5.32	30.200	50.300
2024521x	4	AB- CELL-D	3 MONOCYTE	8	CELL-DYN	48	6.421	1.003	15.62	4.400	8.400
2024521x	4	AB- CELL-D	3 MONOCYTE	37	ABB.CEL RU	42	6.905	1.006	14.57	4.900	8.900
2024521x	4	AB- CELL-D	4 EOSINOPHIL	8	CELL-DYN	48	3.254	0.308	9.45	1.300	5.300
2024521x	4	AB- CELL-D	4 EOSINOPHIL	37	ABB.CEL RU	42	3.062	0.289	9.43	1.100	5.100
2024521x	4	AB- CELL-D	5 BASOPHIL	8	CELL-DYN	48	1.465	0.589	40.21	0	3.500

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024521x	4	AB- CELL-D	5	BASOPHIL	37	ABB.CEL RU	42	0.576	0.406	70.43	0	2.600
2024521x	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	58	56.029	0.956	1.71	42.000	70.000
2024521x	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	58	29.645	1.649	5.56	22.200	37.100
2024521x	5	BECTON D	3	MONOCYTE	29	B.C600,800	58	6.831	0.995	14.56	4.800	8.800
2024521x	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	58	7.512	0.412	5.48	5.500	9.500
2024521x	5	BECTON D	5	BASOPHIL	29	B.C600,800	58	0.000	0.000	0.00	0	2.000
2024521x	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	63	48.286	1.096	2.27	36.200	60.400
2024521x	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	63	39.908	1.748	4.38	29.900	49.900
2024521x	6	MR Mindray	3	MONOCYTE	32	BC-5390	63	6.452	1.104	17.11	4.500	8.500
2024521x	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	63	5.242	0.490	9.36	3.200	7.200
2024521x	6	MR Mindray	5	BASOPHIL	32	BC-5390	63	28.840	0.510	1.77	21.600	36.100
2024521x	7	DXH	1	NEUTROPHIL	36	BC DXH 500	91	69.075	1.729	2.50	51.800	86.300
2024521x	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	91	26.191	1.795	6.85	19.600	32.700
2024521x	7	DXH	3	MONOCYTE	36	BC DXH 500	91	0.192	0.209	109.01	0	2.200
2024521x	7	DXH	4	EOSINOPHIL	36	BC DXH 500	91	4.109	0.416	10.13	2.100	6.100
2024521x	7	DXH	5	BASOPHIL	36	BC DXH 500	91	0.382	0.592	154.90	0	2.400
172 DIFF. WBC FOR 5 PAR.			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2024522x	1	SYSMEX CBC	1	NEUTROPHIL	25	XS SERIES	124	54.553	1.063	1.95	40.900	68.200
2024522x	1	SYSMEX CBC	2	LYMPHOCYTE	25	XS SERIES	124	21.088	0.623	2.95	15.800	26.400
2024522x	1	SYSMEX CBC	3	MONOCYTE	25	XS SERIES	124	1.342	0.267	19.90	0	3.300
2024522x	1	SYSMEX CBC	4	EOSINOPHIL	25	XS SERIES	124	13.786	0.640	4.64	10.300	17.200
2024522x	1	SYSMEX CBC	5	BASOPHIL	25	XS SERIES	124	9.224	0.845	9.16	6.900	11.500
2024522x	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	77	46.089	2.964	6.43	34.600	57.600
2024522x	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	29	45.983	2.387	5.19	34.500	57.500
2024522x	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	77	45.039	2.780	6.17	33.800	56.300
2024522x	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	29	42.669	2.670	6.26	32.000	53.300
2024522x	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	77	2.089	0.544	26.06	0.100	4.100
2024522x	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	30	2.140	0.385	18.00	0.100	4.100
2024522x	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	77	6.683	0.705	10.56	4.700	8.700
2024522x	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	29	6.325	0.789	12.47	4.300	8.300
2024522x	2	ACT PENTRA	5	BASOPHIL	15	COUL ACT 5	78	53.403	1.338	2.51	40.100	66.800



**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024522x	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	29	2.700	0.083	3.08	0.700	4.700		
2024522x	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	17	49.047	1.012	2.06	36.800	61.300		
2024522x	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	17	29.535	1.140	3.86	22.200	36.900		
2024522x	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	17	14.641	0.911	6.22	11.000	18.300		
2024522x	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	17	0.312	0.301	96.47	0	2.300		
2024522x	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	17	1.147	0.341	29.77	0	3.100		
2024522x	3 ADVIA 120	6 LUC	9 ADVIA-120	17	5.853	0.669	11.43	3.900	7.900		
2024522x	4 AB- CELL-D	1 NEUTROPHIL	8 CELL-DYN	48	69.510	0.807	1.16	52.100	86.900		
2024522x	4 AB- CELL-D	1 NEUTROPHIL	37 ABB.CEL RU	42	68.715	0.805	1.17	51.500	85.900		
2024522x	4 AB- CELL-D	2 LYMPHOCYTE	8 CELL-DYN	48	16.370	1.040	6.35	12.300	20.500		
2024522x	4 AB- CELL-D	2 LYMPHOCYTE	37 ABB.CEL RU	42	17.679	1.175	6.65	13.300	22.100		
2024522x	4 AB- CELL-D	3 MONOCYTE	8 CELL-DYN	48	7.694	0.377	4.90	5.700	9.700		
2024522x	4 AB- CELL-D	3 MONOCYTE	37 ABB.CEL RU	42	7.815	0.495	6.34	5.800	9.800		
2024522x	4 AB- CELL-D	4 EOSINOPHIL	8 CELL-DYN	48	5.654	0.268	4.73	3.700	7.700		
2024522x	4 AB- CELL-D	4 EOSINOPHIL	37 ABB.CEL RU	42	5.480	0.218	3.97	3.500	7.500		
2024522x	4 AB- CELL-D	5 BASOPHIL	8 CELL-DYN	48	0.667	0.258	38.77	0	2.700		
2024522x	4 AB- CELL-D	5 BASOPHIL	37 ABB.CEL RU	42	0.300	0.176	58.64	0	2.300		
2024522x	5 BECTON D	1 NEUTROPHIL	29 B.C600,800	58	68.955	0.853	1.24	51.700	86.200		
2024522x	5 BECTON D	2 LYMPHOCYTE	29 B.C600,800	58	20.045	0.761	3.80	15.000	25.100		
2024522x	5 BECTON D	3 MONOCYTE	29 B.C600,800	58	7.131	0.661	9.27	5.100	9.100		
2024522x	5 BECTON D	4 EOSINOPHIL	29 B.C600,800	58	3.779	0.261	6.91	1.800	5.800		
2024522x	5 BECTON D	5 BASOPHIL	29 B.C600,800	58	0.090	0.040	44.85	0	2.100		
2024522x	6 MR Mindray	1 NEUTROPHIL	32 BC-5390	63	63.532	1.050	1.65	47.600	79.400		
2024522x	6 MR Mindray	2 LYMPHOCYTE	32 BC-5390	63	19.811	1.109	5.60	14.900	24.800		
2024522x	6 MR Mindray	3 MONOCYTE	32 BC-5390	63	7.275	0.919	12.63	5.300	9.300		
2024522x	6 MR Mindray	4 EOSINOPHIL	32 BC-5390	63	9.390	0.421	4.49	7.000	11.700		
2024522x	6 MR Mindray	5 BASOPHIL	32 BC-5390	63	31.619	0.229	0.73	23.700	39.500		
2024522x	7 DXH	1 NEUTROPHIL	36 BC DXH 500	91	49.742	4.910	9.87	37.300	62.200		
2024522x	7 DXH	2 LYMPHOCYTE	36 BC DXH 500	90	36.839	5.121	13.90	27.600	46.000		
2024522x	7 DXH	3 MONOCYTE	36 BC DXH 500	91	0.128	0.192	150.64	0	2.100		
2024522x	7 DXH	4 EOSINOPHIL	36 BC DXH 500	91	13.046	1.121	8.59	9.800	16.300		

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024522x	7 DXH	5 BASOPHIL	36 BC DXH 500	91	0.120	0.316	262.79	0	2.100		
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2024523x	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	124	54.683	1.109	2.03	41.000	68.400		
2024523x	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	124	20.835	0.570	2.74	15.600	26.000		
2024523x	1 SYSMEX CBC	3 MONOCYTE	25 XS SERIES	124	1.328	0.270	20.30	0	3.300		
2024523x	1 SYSMEX CBC	4 EOSINOPHIL	25 XS SERIES	124	13.828	0.696	5.04	10.400	17.300		
2024523x	1 SYSMEX CBC	5 BASOPHIL	25 XS SERIES	124	9.342	0.752	8.05	7.000	11.700		
2024523x	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	77	46.207	3.017	6.53	34.700	57.800		
2024523x	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	29	45.876	2.284	4.98	34.400	57.300		
2024523x	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	77	44.866	2.786	6.21	33.600	56.100		
2024523x	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	29	42.690	2.520	5.90	32.000	53.400		
2024523x	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	77	2.014	0.475	23.56	0.000	4.000		
2024523x	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	29	2.262	0.415	18.33	0.300	4.300		
2024523x	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	78	6.843	0.615	8.98	4.800	8.800		
2024523x	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	29	6.282	0.893	14.22	4.300	8.300		
2024523x	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	76	53.323	1.272	2.39	40.000	66.700		
2024523x	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	29	2.696	0.057	2.10	0.700	4.700		
2024523x	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	17	48.929	1.100	2.25	36.700	61.200		
2024523x	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	17	29.700	1.231	4.14	22.300	37.100		
2024523x	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	17	14.759	0.734	4.97	11.100	18.400		
2024523x	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	17	0.335	0.206	61.33	0	2.300		
2024523x	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	17	1.071	0.295	27.52	0	3.100		
2024523x	3 ADVIA 120	6 LUC	9 ADVIA-120	17	5.671	0.739	13.04	3.700	7.700		
2024523x	4 AB- CELL-D	1 NEUTROPHIL	8 CELL-DYN	48	72.117	0.787	1.09	54.100	90.100		
2024523x	4 AB- CELL-D	1 NEUTROPHIL	37 ABB.CEL RU	42	71.490	0.816	1.14	53.600	89.400		
2024523x	4 AB- CELL-D	2 LYMPHOCYTE	8 CELL-DYN	48	14.083	0.915	6.50	10.600	17.600		
2024523x	4 AB- CELL-D	2 LYMPHOCYTE	37 ABB.CEL RU	42	14.930	1.536	10.29	11.200	18.700		
2024523x	4 AB- CELL-D	3 MONOCYTE	8 CELL-DYN	48	4.806	0.403	8.38	2.800	6.800		
2024523x	4 AB- CELL-D	3 MONOCYTE	37 ABB.CEL RU	42	4.795	0.330	6.88	2.800	6.800		
2024523x	4 AB- CELL-D	4 EOSINOPHIL	8 CELL-DYN	48	8.317	0.282	3.39	6.200	10.400		
2024523x	4 AB- CELL-D	4 EOSINOPHIL	37 ABB.CEL RU	39	8.158	0.284	3.48	6.100	10.200		

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2024523x	4	AB- CELL-D	5	BASOPHIL	8	CELL-DYN	48	0.626	0.192	30.67	0	2.600
2024523x	4	AB- CELL-D	5	BASOPHIL	37	ABB.CEL RU	42	0.410	0.167	40.86	0	2.400
2024523x	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	58	68.751	0.665	0.97	51.600	85.900
2024523x	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	58	20.435	0.596	2.92	15.300	25.500
2024523x	5	BECTON D	3	MONOCYTE	29	B.C600,800	58	6.809	0.615	9.04	4.800	8.800
2024523x	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	58	3.928	0.252	6.41	1.900	5.900
2024523x	5	BECTON D	5	BASOPHIL	29	B.C600,800	58	0.091	0.043	46.71	0	2.100
2024523x	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	63	63.374	0.904	1.43	47.500	79.200
2024523x	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	63	19.908	0.951	4.78	14.900	24.900
2024523x	6	MR Mindray	3	MONOCYTE	32	BC-5390	63	7.313	0.794	10.85	5.300	9.300
2024523x	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	63	9.427	0.428	4.54	7.100	11.800
2024523x	6	MR Mindray	5	BASOPHIL	32	BC-5390	63	31.584	0.203	0.64	23.700	39.500
2024523x	7	DXH	1	NEUTROPHIL	36	BC DXH 500	92	49.866	4.956	9.94	37.400	62.300
2024523x	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	90	36.769	5.218	14.19	27.600	46.000
2024523x	7	DXH	3	MONOCYTE	36	BC DXH 500	91	0.108	0.111	102.83	0	2.100
2024523x	7	DXH	4	EOSINOPHIL	36	BC DXH 500	92	12.997	1.125	8.66	9.700	16.200
2024523x	7	DXH	5	BASOPHIL	36	BC DXH 500	89	0.053	0.155	293.31	0	2.100
172 DIFF. WBC FOR 5 PAR.			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2024524x	1	SYSMEX CBC	1	NEUTROPHIL	25	XS SERIES	124	60.166	1.348	2.24	45.100	75.200
2024524x	1	SYSMEX CBC	2	LYMPHOCYTE	25	XS SERIES	124	13.607	1.389	10.21	10.200	17.000
2024524x	1	SYSMEX CBC	3	MONOCYTE	25	XS SERIES	124	0.919	0.261	28.38	0	2.900
2024524x	1	SYSMEX CBC	4	EOSINOPHIL	25	XS SERIES	124	15.857	0.393	2.48	11.900	19.800
2024524x	1	SYSMEX CBC	5	BASOPHIL	25	XS SERIES	124	9.353	0.853	9.11	7.000	11.700
2024524x	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	77	71.694	0.905	1.26	53.800	89.600
2024524x	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	29	68.755	1.034	1.50	51.600	85.900
2024524x	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	77	21.840	0.765	3.50	16.400	27.300
2024524x	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	29	20.883	0.842	4.03	15.700	26.100
2024524x	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	77	1.520	0.385	25.33	0	3.500
2024524x	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	29	1.448	0.301	20.80	0	3.400
2024524x	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	77	4.905	0.385	7.85	2.900	6.900
2024524x	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	29	4.986	0.256	5.13	3.000	7.000

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024524x	2	ACT PENTRA	5 BASOPHIL	15	COUL ACT 5	77	79.032	1.056	1.34	59.300	98.800
2024524x	2	ACT PENTRA	5 BASOPHIL	24	ABX PENTRA	29	3.986	0.082	2.05	2.000	6.000
2024524x	3	ADVIA 120	1 NEUTROPHIL	9	ADVIA-120	17	75.471	0.709	0.94	56.600	94.300
2024524x	3	ADVIA 120	2 LYMPHOCYTE	9	ADVIA-120	17	12.388	0.403	3.25	9.300	15.500
2024524x	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	17	8.429	0.469	5.56	6.300	10.500
2024524x	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	17	0.635	0.084	13.16	0	2.600
2024524x	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	17	0.794	0.236	29.76	0	2.800
2024524x	3	ADVIA 120	6 LUC	9	ADVIA-120	17	2.659	0.289	10.87	0.700	4.700
2024524x	4	AB- CELL-D	1 NEUTROPHIL	8	CELL-DYN	48	51.651	1.345	2.60	38.700	64.600
2024524x	4	AB- CELL-D	1 NEUTROPHIL	37	ABB.CEL RU	42	49.733	1.720	3.46	37.300	62.200
2024524x	4	AB- CELL-D	2 LYMPHOCYTE	8	CELL-DYN	48	37.652	2.339	6.21	28.200	47.100
2024524x	4	AB- CELL-D	2 LYMPHOCYTE	37	ABB.CEL RU	41	39.379	1.984	5.04	29.500	49.200
2024524x	4	AB- CELL-D	3 MONOCYTE	8	CELL-DYN	48	6.265	1.068	17.04	4.300	8.300
2024524x	4	AB- CELL-D	3 MONOCYTE	37	ABB.CEL RU	40	6.761	1.387	20.52	4.800	8.800
2024524x	4	AB- CELL-D	4 EOSINOPHIL	8	CELL-DYN	48	3.248	0.329	10.13	1.200	5.200
2024524x	4	AB- CELL-D	4 EOSINOPHIL	37	ABB.CEL RU	42	3.368	0.597	17.73	1.400	5.400
2024524x	4	AB- CELL-D	5 BASOPHIL	8	CELL-DYN	48	1.321	0.611	46.26	0	3.300
2024524x	4	AB- CELL-D	5 BASOPHIL	37	ABB.CEL RU	42	0.595	0.348	58.44	0	2.600
2024524x	5	BECTON D	1 NEUTROPHIL	29	B.C600,800	58	55.760	1.035	1.86	41.800	69.700
2024524x	5	BECTON D	2 LYMPHOCYTE	29	B.C600,800	58	29.737	1.618	5.44	22.300	37.200
2024524x	5	BECTON D	3 MONOCYTE	29	B.C600,800	58	6.907	0.913	13.21	4.900	8.900
2024524x	5	BECTON D	4 EOSINOPHIL	29	B.C600,800	58	7.498	0.363	4.84	5.500	9.500
2024524x	5	BECTON D	5 BASOPHIL	29	B.C600,800	58	0.000	0.000	0.00	0	2.000
2024524x	6	MR Mindray	1 NEUTROPHIL	32	BC-5390	63	47.906	1.127	2.35	35.900	59.900
2024524x	6	MR Mindray	2 LYMPHOCYTE	32	BC-5390	63	40.398	1.407	3.48	30.300	50.500
2024524x	6	MR Mindray	3 MONOCYTE	32	BC-5390	63	6.297	1.029	16.34	4.300	8.300
2024524x	6	MR Mindray	4 EOSINOPHIL	32	BC-5390	63	5.185	0.386	7.45	3.200	7.200
2024524x	6	MR Mindray	5 BASOPHIL	32	BC-5390	63	28.790	0.515	1.79	21.600	36.000
2024524x	7	DXH	1 NEUTROPHIL	36	BC DXH 500	91	77.993	1.018	1.31	58.500	97.500
2024524x	7	DXH	2 LYMPHOCYTE	36	BC DXH 500	91	12.380	1.254	10.13	9.300	15.500
2024524x	7	DXH	3 MONOCYTE	36	BC DXH 500	91	0.257	0.200	77.70	0	2.300

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024524x	7 DXH	4 EOSINOPHIL	36 BC DXH 500	91	9.212	0.516	5.60	6.900	11.500		
2024524x	7 DXH	5 BASOPHIL	36 BC DXH 500	91	0.138	0.245	177.41	0	2.100		
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765	EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}								
2024525x	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	124	51.496	1.275	2.48	38.600	64.400		
2024525x	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	124	25.416	1.180	4.64	19.100	31.800		
2024525x	1 SYSMEX CBC	3 MONOCYTE	25 XS SERIES	124	1.029	0.341	33.13	0	3.000		
2024525x	1 SYSMEX CBC	4 EOSINOPHIL	25 XS SERIES	124	13.774	0.398	2.89	10.300	17.200		
2024525x	1 SYSMEX CBC	5 BASOPHIL	25 XS SERIES	124	8.221	0.727	8.84	6.200	10.300		
2024525x	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	77	53.387	1.095	2.05	40.000	66.700		
2024525x	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	29	51.717	1.283	2.48	38.800	64.600		
2024525x	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	77	41.881	0.924	2.21	31.400	52.400		
2024525x	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	29	40.486	1.288	3.18	30.400	50.600		
2024525x	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	77	1.261	0.282	22.40	0	3.300		
2024525x	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	29	1.303	0.179	13.74	0	3.300		
2024525x	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	77	3.542	0.351	9.92	1.500	5.500		
2024525x	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	29	3.589	0.213	5.93	1.600	5.600		
2024525x	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	77	57.076	0.967	1.69	42.800	71.300		
2024525x	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	29	2.907	0.069	2.38	0.900	4.900		
2024525x	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	17	65.353	0.813	1.24	49.000	81.700		
2024525x	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	17	21.241	0.784	3.69	15.900	26.600		
2024525x	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	17	8.235	0.556	6.75	6.200	10.300		
2024525x	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	17	0.288	0.078	27.15	0	2.300		
2024525x	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	17	0.724	0.326	45.11	0	2.700		
2024525x	3 ADVIA 120	6 LUC	9 ADVIA-120	17	4.429	0.629	14.21	2.400	6.400		
2024525x	4 AB- CELL-D	1 NEUTROPHIL	8 CELL-DYN	48	67.275	0.981	1.46	50.500	84.100		
2024525x	4 AB- CELL-D	1 NEUTROPHIL	37 ABB.CEL RU	42	67.438	2.269	3.37	50.600	84.300		
2024525x	4 AB- CELL-D	2 LYMPHOCYTE	8 CELL-DYN	48	21.708	1.292	5.95	16.300	27.100		
2024525x	4 AB- CELL-D	2 LYMPHOCYTE	37 ABB.CEL RU	42	21.859	3.704	16.94	16.400	27.300		
2024525x	4 AB- CELL-D	3 MONOCYTE	8 CELL-DYN	48	6.179	0.648	10.49	4.200	8.200		
2024525x	4 AB- CELL-D	3 MONOCYTE	37 ABB.CEL RU	42	5.052	1.759	34.81	3.100	7.100		
2024525x	4 AB- CELL-D	4 EOSINOPHIL	8 CELL-DYN	48	4.192	0.245	5.84	2.200	6.200		

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD		SYST/INST	REAGENTS			NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024525x	4	AB- CELL-D	4	EOSINOPHIL	37	ABB.CEL RU	42	4.349	0.625	14.37	2.300	6.300
2024525x	4	AB- CELL-D	5	BASOPHIL	8	CELL-DYN	48	0.683	0.340	49.75	0	2.700
2024525x	4	AB- CELL-D	5	BASOPHIL	37	ABB.CEL RU	42	0.339	0.638	188.12	0	2.300
2024525x	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	58	59.866	0.852	1.42	44.900	74.800
2024525x	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	58	28.948	1.098	3.79	21.700	36.200
2024525x	5	BECTON D	3	MONOCYTE	29	B.C600,800	58	5.348	0.575	10.76	3.300	7.300
2024525x	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	58	5.807	0.275	4.74	3.800	7.800
2024525x	5	BECTON D	5	BASOPHIL	29	B.C600,800	58	0.031	0.046	149.07	0	2.000
2024525x	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	62	54.685	0.809	1.48	41.000	68.400
2024525x	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	62	29.777	1.532	5.15	22.300	37.200
2024525x	6	MR Mindray	3	MONOCYTE	32	BC-5390	63	6.838	1.075	15.73	4.800	8.800
2024525x	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	63	8.610	0.411	4.77	6.500	10.800
2024525x	6	MR Mindray	5	BASOPHIL	32	BC-5390	62	29.071	0.284	0.98	21.800	36.300
2024525x	7	DXH	1	NEUTROPHIL	36	BC DXH 500	91	69.334	1.990	2.87	52.000	86.700
2024525x	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	91	25.974	1.943	7.48	19.500	32.500
2024525x	7	DXH	3	MONOCYTE	36	BC DXH 500	91	0.218	0.252	115.88	0	2.200
2024525x	7	DXH	4	EOSINOPHIL	36	BC DXH 500	91	4.085	0.370	9.07	2.100	6.100
2024525x	7	DXH	5	BASOPHIL	36	BC DXH 500	91	0.359	0.566	157.42	0	2.400

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE												
SAMPLE	METHOD		SYST/INST	REAGENTS			NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
185 Diff 6 Parameter Ins			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2024521y	1	6 PAR REG	1	NEUTROPHIL	31	SYSMEX XN	50	63.520	2.013	3.17	47.600	79.400
2024521y	1	6 PAR REG	1	NEUTROPHIL	35	SYS XNL SR	211	59.500	1.215	2.04	44.600	74.400
2024521y	1	6 PAR REG	2	LYMPHOCYTE	31	SYSMEX XN	52	13.878	0.728	5.25	10.400	17.300
2024521y	1	6 PAR REG	2	LYMPHOCYTE	35	SYS XNL SR	211	15.075	0.753	5.00	11.300	18.800

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 127 DIFF 6 PARAM INSTRUM									
ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
2024521y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	51	1.546	0.373	24.11	0	3.500				
2024521y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	211	0.717	0.203	28.32	0	2.700				
2024521y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	51	15.692	0.663	4.22	11.800	19.600				
2024521y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	211	15.453	0.833	5.39	11.600	19.300				
2024521y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	51	5.173	1.143	22.09	3.200	7.200				
2024521y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	211	9.236	0.849	9.19	6.900	11.500				
2024521y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	51	16.002	0.765	4.78	12.000	20.000				
2024521y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	211	16.443	1.025	6.23	12.300	20.600				
2024521y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	23	0.036	0.093	256.17	0	2.000				
185 Diff 6 Parameter Ins		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}									
2024522y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	51	58.851	1.438	2.44	44.100	73.600				
2024522y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	211	55.258	1.064	1.92	41.400	69.100				
2024522y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	51	19.280	0.586	3.04	14.500	24.100				
2024522y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	209	20.373	0.437	2.15	15.300	25.500				
2024522y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	51	2.232	0.413	18.48	0.200	4.200				
2024522y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	210	1.232	0.202	16.42	0	3.200				
2024522y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	51	14.408	0.730	5.06	10.800	18.000				
2024522y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	210	14.470	0.761	5.26	10.900	18.100				
2024522y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	51	5.241	1.263	24.11	3.200	7.200				
2024522y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	210	8.700	0.728	8.37	6.500	10.900				
2024522y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	51	14.934	0.802	5.37	11.200	18.700				
2024522y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	209	15.370	0.932	6.06	11.500	19.200				
2024522y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	24	1.033	0.493	47.71	0	3.000				
2024523y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	50	59.196	1.448	2.45	44.400	74.000				
2024523y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	210	55.476	1.035	1.87	41.600	69.300				
2024523y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	51	19.004	0.530	2.79	14.300	23.800				
2024523y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	210	20.106	0.412	2.05	15.100	25.100				
2024523y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	51	2.186	0.373	17.04	0.200	4.200				
2024523y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	211	1.224	0.223	18.21	0	3.200				

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024523y	1 6 PAR REG	4	EOSINOPHIL	31	SYSMEX XN	49	14.419	0.772	5.35	10.800	18.000
2024523y	1 6 PAR REG	4	EOSINOPHIL	35	SYS XNL SR	210	14.498	0.768	5.30	10.900	18.100
2024523y	1 6 PAR REG	5	BASOPHIL	31	SYSMEX XN	51	5.131	1.065	20.76	3.100	7.100
2024523y	1 6 PAR REG	5	BASOPHIL	35	SYS XNL SR	208	8.730	0.761	8.72	6.500	10.900
2024523y	1 6 PAR REG	6	IMMATURE G	31	SYSMEX XN	51	15.192	0.843	5.55	11.400	19.000
2024523y	1 6 PAR REG	6	IMMATURE G	35	SYS XNL SR	211	15.431	0.986	6.39	11.600	19.300
2024523y	1 6 PAR REG	7	NRBC	31	SYSMEX XN	24	0.625	0.385	61.67	0	2.600
185 Diff 6 Parameter Ins		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2024524y	1 6 PAR REG	1	NEUTROPHIL	31	SYSMEX XN	51	63.635	1.341	2.11	47.700	79.500
2024524y	1 6 PAR REG	1	NEUTROPHIL	35	SYS XNL SR	210	59.447	1.269	2.13	44.600	74.300
2024524y	1 6 PAR REG	2	LYMPHOCYTE	31	SYSMEX XN	51	13.850	0.688	4.97	10.400	17.300
2024524y	1 6 PAR REG	2	LYMPHOCYTE	35	SYS XNL SR	210	15.134	0.743	4.91	11.400	18.900
2024524y	1 6 PAR REG	3	MONOCYTE	31	SYSMEX XN	51	1.566	0.457	29.17	0	3.600
2024524y	1 6 PAR REG	3	MONOCYTE	35	SYS XNL SR	210	0.721	0.227	31.54	0	2.700
2024524y	1 6 PAR REG	4	EOSINOPHIL	31	SYSMEX XN	51	15.626	0.815	5.21	11.700	19.500
2024524y	1 6 PAR REG	4	EOSINOPHIL	35	SYS XNL SR	209	15.480	0.750	4.85	11.600	19.300
2024524y	1 6 PAR REG	5	BASOPHIL	31	SYSMEX XN	51	5.306	1.331	25.08	3.300	7.300
2024524y	1 6 PAR REG	5	BASOPHIL	35	SYS XNL SR	211	9.243	0.871	9.43	6.900	11.600
2024524y	1 6 PAR REG	6	IMMATURE G	31	SYSMEX XN	51	15.960	0.754	4.73	12.000	20.000
2024524y	1 6 PAR REG	6	IMMATURE G	35	SYS XNL SR	210	16.443	0.928	5.64	12.300	20.600
2024524y	1 6 PAR REG	7	NRBC	31	SYSMEX XN	23	0.000	0.000	0.00	0	2.000
2024525y	1 6 PAR REG	1	NEUTROPHIL	31	SYSMEX XN	51	54.662	1.591	2.91	41.000	68.300
2024525y	1 6 PAR REG	1	NEUTROPHIL	35	SYS XNL SR	211	51.693	1.037	2.01	38.800	64.600
2024525y	1 6 PAR REG	2	LYMPHOCYTE	31	SYSMEX XN	50	24.155	0.746	3.09	18.100	30.200
2024525y	1 6 PAR REG	2	LYMPHOCYTE	35	SYS XNL SR	210	25.614	0.680	2.65	19.200	32.000
2024525y	1 6 PAR REG	3	MONOCYTE	31	SYSMEX XN	50	2.084	0.472	22.66	0.100	4.100
2024525y	1 6 PAR REG	3	MONOCYTE	35	SYS XNL SR	211	1.043	0.269	25.78	0	3.000
2024525y	1 6 PAR REG	4	EOSINOPHIL	31	SYSMEX XN	51	13.836	0.579	4.18	10.400	17.300
2024525y	1 6 PAR REG	4	EOSINOPHIL	35	SYS XNL SR	208	13.607	0.608	4.47	10.200	17.000



**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024525y	1	6 PAR REG	5	BASOPHIL	31	SYSMEX XN	51	5.108	0.885	17.32	3.100	7.100
2024525y	1	6 PAR REG	5	BASOPHIL	35	SYS XNL SR	210	8.092	0.669	8.27	6.100	10.100
2024525y	1	6 PAR REG	6	IMMATURE G	31	SYSMEX XN	51	13.824	0.654	4.73	10.400	17.300
2024525y	1	6 PAR REG	6	IMMATURE G	35	SYS XNL SR	210	14.053	0.731	5.20	10.500	17.600
2024525y	1	6 PAR REG	7	NRBC	31	SYSMEX XN	23	0.055	0.084	153.66	0	2.100

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 128 DIFF 3 PARAMETER INS

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
186 DIFF 3 PARAMETER INS			CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE			25 % OR 2.00 {GREATER}				
2024521z	8	3ST	1	Lymphocyte	1	KX 21 - Sy	18	61.071	0.986	1.61	45.800	76.300
2024521z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	21	59.919	0.864	1.44	44.900	74.900
2024521z	8	3ST	2	Mix M/E/Ba	1	KX 21 - Sy	18	14.536	0.853	5.87	10.900	18.200
2024521z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	21	10.276	0.834	8.12	7.700	12.800
2024521z	8	3ST	3	Neutrophil	1	KX 21 - Sy	18	24.393	1.258	5.16	18.300	30.500
2024521z	8	3ST	3	Neutrophil	3	ABBOTT C-D	21	29.800	1.012	3.40	22.400	37.300
2024522z	8	3ST	1	Lymphocyte	1	KX 21 - Sy	18	12.293	1.558	12.67	9.200	15.400
2024522z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	21	13.800	1.501	10.87	10.400	17.300
2024522z	8	3ST	2	Mix M/E/Ba	1	KX 21 - Sy	18	17.907	1.514	8.46	13.400	22.400
2024522z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	21	11.648	1.123	9.64	8.700	14.600
2024522z	8	3ST	3	Neutrophil	1	KX 21 - Sy	18	69.800	2.487	3.56	52.400	87.300
2024522z	8	3ST	3	Neutrophil	3	ABBOTT C-D	21	74.785	1.942	2.60	56.100	93.500
2024523z	8	3ST	1	Lymphocyte	1	KX 21 - Sy	18	61.657	0.651	1.06	46.200	77.100
2024523z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	21	59.871	1.067	1.78	44.900	74.800
2024523z	8	3ST	2	Mix M/E/Ba	1	KX 21 - Sy	18	13.900	0.566	4.07	10.400	17.400
2024523z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	21	10.181	0.686	6.73	7.600	12.700
2024523z	8	3ST	3	Neutrophil	1	KX 21 - Sy	17	24.546	0.799	3.25	18.400	30.700

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 128 DIFF 3 PARAMETER INS									
ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
2024523z	8 3ST	3	Neutrophil	3	ABBOTT C-D	21	29.962	1.069	3.57	22.500	37.500		
186 DIFF 3 PARAMETER INS			CLIA TEST ID #: 765 EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}										
2024524z	8 3ST	1	Lymphocyte	1	KX 21 - Sy	18	29.793	0.777	2.61	22.300	37.200		
2024524z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	21	30.185	0.958	3.17	22.600	37.700		
2024524z	8 3ST	2	Mix M/E/Ba	1	KX 21 - Sy	18	18.107	1.649	9.11	13.600	22.600		
2024524z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	21	12.005	1.063	8.86	9.000	15.000		
2024524z	8 3ST	3	Neutrophil	1	KX 21 - Sy	18	52.100	1.687	3.24	39.100	65.100		
2024524z	8 3ST	3	Neutrophil	3	ABBOTT C-D	21	57.985	1.470	2.54	43.500	72.500		
2024525z	8 3ST	1	Lymphocyte	1	KX 21 - Sy	18	12.236	1.385	11.32	9.200	15.300		
2024525z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	21	12.838	1.143	8.90	9.600	16.000		
2024525z	8 3ST	2	Mix M/E/Ba	1	KX 21 - Sy	18	18.664	1.524	8.16	14.000	23.300		
2024525z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	21	11.710	1.389	11.87	8.800	14.600		
2024525z	8 3ST	3	Neutrophil	1	KX 21 - Sy	18	69.631	1.040	1.49	52.200	87.000		
2024525z	8 3ST	3	Neutrophil	3	ABBOTT C-D	21	75.429	1.897	2.51	56.600	94.300		

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW									
ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
549 RED CELL COUNT (RBC)			CLIA TEST ID #: 775 EVALUATION CRITERIA: TARGET VALUE 6 %										
2024-521	1 Sysmex CBC	132	SYSMEX XS	124	2.349	0.031	1.33	2.210	2.490				
2024-521	1 Sysmex CBC	141	SYSMEX XN	50	2.334	0.030	1.30	2.190	2.470				
2024-521	1 Sysmex CBC	152	Sysmex XN	216	2.316	0.029	1.26	2.180	2.460				
2024-521	2 ACT PENTRA	125	COULTER AC	76	4.594	0.078	1.69	4.320	4.870				
2024-521	2 ACT PENTRA	130	ABX PENTRA	29	4.534	0.072	1.59	4.260	4.810				
2024-521	3 ADVIA 120	116	ADVIA-120	17	4.256	0.098	2.30	4.000	4.510				
2024-521	4 AB-CELL DY	115	ABBOTT C-D	39	2.142	0.051	2.39	2.010	2.270				
2024-521	4 AB-CELL DY	153	AB-CEL-RUB	50	2.151	0.074	3.44	2.020	2.280				

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-521	5	BECTON D	137 B.C DXH	58	2.527	0.037	1.46	2.380	2.680
2024-521	6	MR Mindray	145 BC-5390	63	2.195	0.040	1.81	2.060	2.330
2024-521	7	DXH500 Ser	149 BC DXH 500	92	4.652	0.077	1.65	4.370	4.930
2024-521	8	3 ST	84 ABBOTT C-D	21	5.774	0.147	2.55	5.430	6.120
2024-521	8	3 ST	138 SY KX-21N	14	5.804	0.096	1.66	5.460	6.150
549	RED CELL COUNT (RBC)	CLIA TEST ID #: 775	EVALUATION CRITERIA: TARGET VALUE 6 %						
2024-522	1	Sysmex CBC	132 SYSMEX XS	124	6.425	0.081	1.26	6.040	6.810
2024-522	1	Sysmex CBC	141 SYSMEX XN	50	6.453	0.065	1.01	6.070	6.840
2024-522	1	Sysmex CBC	152 Sysmex XN	216	6.475	0.079	1.22	6.090	6.860
2024-522	2	ACT PENTRA	125 COULTER AC	76	2.388	0.045	1.90	2.240	2.530
2024-522	2	ACT PENTRA	130 ABX PENTRA	29	2.374	0.047	2.00	2.230	2.520
2024-522	3	ADVIA 120	116 ADVIA-120	17	2.078	0.032	1.56	1.950	2.200
2024-522	4	AB-CELL DY	115 ABBOTT C-D	39	6.182	0.111	1.80	5.810	6.550
2024-522	4	AB-CELL DY	153 AB-CEL-RUB	50	6.367	0.123	1.93	5.980	6.750
2024-522	5	BECTON D	137 B.C DXH	58	6.305	0.082	1.30	5.930	6.680
2024-522	6	MR Mindray	145 BC-5390	63	5.351	0.105	1.96	5.030	5.670
2024-522	7	DXH500 Ser	149 BC DXH 500	92	2.374	0.039	1.65	2.230	2.520
2024-522	8	3 ST	84 ABBOTT C-D	21	2.432	0.061	2.51	2.290	2.580
2024-522	8	3 ST	138 SY KX-21N	14	2.423	0.032	1.32	2.280	2.570
2024-523	1	Sysmex CBC	132 SYSMEX XS	124	5.715	0.077	1.36	5.370	6.060
2024-523	1	Sysmex CBC	141 SYSMEX XN	50	5.752	0.068	1.19	5.410	6.100
2024-523	1	Sysmex CBC	152 Sysmex XN	216	5.758	0.064	1.12	5.410	6.100
2024-523	2	ACT PENTRA	125 COULTER AC	76	2.387	0.042	1.76	2.240	2.530
2024-523	2	ACT PENTRA	130 ABX PENTRA	29	2.380	0.045	1.87	2.240	2.520
2024-523	3	ADVIA 120	116 ADVIA-120	17	2.076	0.037	1.80	1.950	2.200
2024-523	4	AB-CELL DY	115 ABBOTT C-D	39	5.232	0.081	1.55	4.920	5.550
2024-523	4	AB-CELL DY	153 AB-CEL-RUB	50	5.426	0.144	2.65	5.100	5.750
2024-523	5	BECTON D	137 B.C DXH	58	5.446	0.065	1.20	5.120	5.770
2024-523	6	MR Mindray	145 BC-5390	63	5.367	0.105	1.96	5.040	5.690

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-523	7 DXH500 Ser	149 BC DXH 500			92	2.372	0.042	1.79	2.230	2.510	
2024-523	8 3 ST	84 ABBOTT C-D			21	5.767	0.154	2.67	5.420	6.110	
2024-523	8 3 ST	138 SY KX-21N			14	5.826	0.095	1.63	5.480	6.180	
549	RED CELL COUNT (RBC)	CLIA TEST ID #: 775									
									EVALUATION CRITERIA: TARGET VALUE 6 %		
2024-524	1 Sysmex CBC	132 SYSMEX XS			124	2.351	0.032	1.37	2.210	2.490	
2024-524	1 Sysmex CBC	141 SYSMEX XN			50	2.334	0.024	1.05	2.190	2.470	
2024-524	1 Sysmex CBC	152 Sysmex XN			216	2.320	0.029	1.26	2.180	2.460	
2024-524	2 ACT PENTRA	125 COULTER AC			76	5.013	0.060	1.21	4.710	5.310	
2024-524	2 ACT PENTRA	130 ABX PENTRA			29	4.978	0.074	1.48	4.680	5.280	
2024-524	3 ADVIA 120	116 ADVIA-120			17	5.335	0.120	2.24	5.010	5.650	
2024-524	4 AB-CELL DY	115 ABBOTT C-D			39	2.141	0.042	1.94	2.010	2.270	
2024-524	4 AB-CELL DY	153 AB-CEL-RUB			50	2.152	0.090	4.20	2.020	2.280	
2024-524	5 BECTON D	137 B.C DXH			58	2.525	0.033	1.32	2.370	2.680	
2024-524	6 MR Mindray	145 BC-5390			63	2.202	0.037	1.69	2.070	2.330	
2024-524	7 DXH500 Ser	149 BC DXH 500			92	5.116	0.074	1.45	4.810	5.420	
2024-524	8 3 ST	84 ABBOTT C-D			21	4.005	0.098	2.44	3.760	4.250	
2024-524	8 3 ST	138 SY KX-21N			14	3.955	0.087	2.20	3.720	4.190	
2024-525	1 Sysmex CBC	132 SYSMEX XS			124	4.694	0.065	1.39	4.410	4.980	
2024-525	1 Sysmex CBC	141 SYSMEX XN			50	4.709	0.054	1.14	4.430	4.990	
2024-525	1 Sysmex CBC	152 Sysmex XN			216	4.693	0.055	1.16	4.410	4.970	
2024-525	2 ACT PENTRA	125 COULTER AC			76	4.575	0.051	1.12	4.300	4.850	
2024-525	2 ACT PENTRA	130 ABX PENTRA			29	4.531	0.073	1.61	4.260	4.800	
2024-525	3 ADVIA 120	116 ADVIA-120			17	4.252	0.105	2.46	4.000	4.510	
2024-525	4 AB-CELL DY	115 ABBOTT C-D			39	4.679	0.082	1.76	4.400	4.960	
2024-525	4 AB-CELL DY	153 AB-CEL-RUB			50	4.791	0.097	2.02	4.500	5.080	
2024-525	5 BECTON D	137 B.C DXH			58	3.989	0.052	1.30	3.750	4.230	
2024-525	6 MR Mindray	145 BC-5390			63	4.540	0.079	1.74	4.270	4.810	
2024-525	7 DXH500 Ser	149 BC DXH 500			92	4.623	0.067	1.45	4.350	4.900	
2024-525	8 3 ST	84 ABBOTT C-D			21	2.439	0.061	2.52	2.290	2.590	

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-525	8	3 ST		138	SY KX-21N	14	2.409	0.047	1.95	2.260	2.550
550	HEMATOCRIT (HCT)		CLIA TEST ID #: 785		EVALUATION CRITERIA: TARGET VALUE 6 %						
2024-521	1	Sysmex CBC		132	SYSMEX XS	124	18.685	0.432	2.31	17.600	19.800
2024-521	1	Sysmex CBC		141	SYSMEX XN	50	17.967	0.331	1.84	16.900	19.000
2024-521	1	Sysmex CBC		152	Systemex XN	215	18.137	0.303	1.67	17.000	19.200
2024-521	2	ACT PENTRA		125	COULTER AC	76	38.593	0.761	1.97	36.300	40.900
2024-521	2	ACT PENTRA		130	ABX PENTRA	29	38.255	0.697	1.82	36.000	40.600
2024-521	3	ADVIA 120		116	ADVIA-120	17	36.300	0.935	2.58	34.100	38.500
2024-521	4	AB-CELL DY		115	ABBOTT C-D	41	15.588	0.450	2.88	14.700	16.500
2024-521	4	AB-CELL DY		153	AB-CEL-RUB	49	15.708	0.400	2.55	14.800	16.700
2024-521	5	BECTON D		137	B.C DXH	58	20.457	0.330	1.61	19.200	21.700
2024-521	6	MR Mindray		145	BC-5390	63	17.519	0.412	2.35	16.500	18.600
2024-521	7	DXH500 Ser		149	BC DXH 500	92	41.351	0.857	2.07	38.900	43.800
2024-521	8	3 ST		84	ABBOTT C-D	21	52.562	2.018	3.84	49.400	55.700
2024-521	8	3 ST		138	SY KX-21N	14	50.521	0.967	1.91	47.500	53.600
2024-522	1	Sysmex CBC		132	SYSMEX XS	124	59.498	1.363	2.29	55.900	63.100
2024-522	1	Sysmex CBC		141	SYSMEX XN	50	58.551	0.988	1.69	55.000	62.100
2024-522	1	Sysmex CBC		152	Systemex XN	215	58.971	1.088	1.84	55.400	62.500
2024-522	2	ACT PENTRA		125	COULTER AC	76	18.241	0.354	1.94	17.100	19.300
2024-522	2	ACT PENTRA		130	ABX PENTRA	29	18.110	0.374	2.07	17.000	19.200
2024-522	3	ADVIA 120		116	ADVIA-120	17	15.576	0.362	2.33	14.600	16.500
2024-522	4	AB-CELL DY		115	ABBOTT C-D	41	50.860	1.414	2.78	47.800	53.900
2024-522	4	AB-CELL DY		153	AB-CEL-RUB	49	52.898	1.343	2.54	49.700	56.100
2024-522	5	BECTON D		137	B.C DXH	58	65.204	0.882	1.35	61.300	69.100
2024-522	6	MR Mindray		145	BC-5390	63	48.410	1.592	3.29	45.500	51.300
2024-522	7	DXH500 Ser		149	BC DXH 500	92	18.270	0.345	1.89	17.200	19.400
2024-522	8	3 ST		84	ABBOTT C-D	21	17.667	0.706	4.00	16.600	18.700
2024-522	8	3 ST		138	SY KX-21N	14	17.107	0.240	1.41	16.100	18.100

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
550	HEMATOCRIT (HCT)	CLIA TEST ID #: 785		EVALUATION CRITERIA: TARGET VALUE 6 %					
2024-523	1	Sysmex CBC	132 SYSMEX XS	124	53.261	1.228	2.31	50.100	56.500
2024-523	1	Sysmex CBC	141 SYSMEX XN	50	52.210	0.985	1.89	49.100	55.300
2024-523	1	Sysmex CBC	152 Sysmex XN	215	52.600	0.954	1.81	49.400	55.800
2024-523	2	ACT PENTRA	125 COULTER AC	76	18.261	0.402	2.20	17.200	19.400
2024-523	2	ACT PENTRA	130 ABX PENTRA	29	18.131	0.371	2.05	17.000	19.200
2024-523	3	ADVIA 120	116 ADVIA-120	17	15.559	0.426	2.74	14.600	16.500
2024-523	4	AB-CELL DY	115 ABBOTT C-D	41	44.945	1.192	2.65	42.200	47.600
2024-523	4	AB-CELL DY	153 AB-CEL-RUB	49	46.808	1.401	2.99	44.000	49.600
2024-523	5	BECTON D	137 B.C DXH	58	56.350	0.803	1.42	53.000	59.700
2024-523	6	MR Mindray	145 BC-5390	63	48.302	1.543	3.19	45.400	51.200
2024-523	7	DXH500 Ser	149 BC DXH 500	92	18.265	0.353	1.94	17.200	19.400
2024-523	8	3 ST	84 ABBOTT C-D	21	52.600	1.788	3.40	49.400	55.800
2024-523	8	3 ST	138 SY KX-21N	14	50.662	1.031	2.03	47.600	53.700
2024-524	1	Sysmex CBC	132 SYSMEX XS	124	18.684	0.414	2.22	17.600	19.800
2024-524	1	Sysmex CBC	141 SYSMEX XN	50	17.984	0.351	1.95	16.900	19.100
2024-524	1	Sysmex CBC	152 Sysmex XN	215	18.158	0.327	1.80	17.100	19.200
2024-524	2	ACT PENTRA	125 COULTER AC	76	45.380	0.650	1.43	42.700	48.100
2024-524	2	ACT PENTRA	130 ABX PENTRA	29	45.272	0.761	1.68	42.600	48.000
2024-524	3	ADVIA 120	116 ADVIA-120	17	47.471	1.563	3.29	44.600	50.300
2024-524	4	AB-CELL DY	115 ABBOTT C-D	41	15.608	0.413	2.64	14.700	16.500
2024-524	4	AB-CELL DY	153 AB-CEL-RUB	49	15.723	0.540	3.43	14.800	16.700
2024-524	5	BECTON D	137 B.C DXH	58	20.541	0.295	1.44	19.300	21.800
2024-524	6	MR Mindray	145 BC-5390	63	17.511	0.428	2.45	16.500	18.600
2024-524	7	DXH500 Ser	149 BC DXH 500	92	49.068	0.829	1.69	46.100	52.000
2024-524	8	3 ST	84 ABBOTT C-D	21	33.895	1.160	3.42	31.900	35.900
2024-524	8	3 ST	138 SY KX-21N	14	31.577	0.784	2.48	29.700	33.500
2024-525	1	Sysmex CBC	132 SYSMEX XS	124	40.347	0.933	2.31	37.900	42.800

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-525	1	Sysmex CBC	141 SYSMEX XN	50	39.635	0.706	1.78	37.300	42.000		
2024-525	1	Sysmex CBC	152 Sysmex XN	215	39.872	0.710	1.78	37.500	42.300		
2024-525	2	ACT PENTRA	125 COULTER AC	76	38.459	0.635	1.65	36.200	40.800		
2024-525	2	ACT PENTRA	130 ABX PENTRA	29	38.162	0.698	1.83	35.900	40.500		
2024-525	3	ADVIA 120	116 ADVIA-120	17	36.276	1.222	3.37	34.100	38.500		
2024-525	4	AB-CELL DY	115 ABBOTT C-D	41	38.671	1.110	2.87	36.400	41.000		
2024-525	4	AB-CELL DY	153 AB-CEL-RUB	49	39.913	1.334	3.34	37.500	42.300		
2024-525	5	BECTON D	137 B.C DXH	58	38.174	0.503	1.32	35.900	40.500		
2024-525	6	MR Mindray	145 BC-5390	63	38.610	1.178	3.05	36.300	40.900		
2024-525	7	DXH500 Ser	149 BC DXH 500	92	41.090	0.731	1.78	38.600	43.600		
2024-525	8	3 ST	84 ABBOTT C-D	21	17.781	0.718	4.04	16.700	18.800		
2024-525	8	3 ST	138 SY KX-21N	14	16.985	0.390	2.30	16.000	18.000		
551 HEMOGLOBIN (HGB)		CLIA TEST ID #: 795	EVALUATION CRITERIA: TARGET VALUE 7 % OR 2.00 {LOWER}								
2024-521	1	Sysmex CBC	132 SYSMEX XS	125	5.993	0.097	1.62	5.600	6.400		
2024-521	1	Sysmex CBC	141 SYSMEX XN	50	6.065	0.082	1.36	5.600	6.500		
2024-521	1	Sysmex CBC	152 Sysmex XN	214	6.071	0.069	1.13	5.600	6.500		
2024-521	2	ACT PENTRA	125 COULTER AC	76	13.421	0.191	1.42	12.500	14.400		
2024-521	2	ACT PENTRA	130 ABX PENTRA	29	13.341	0.177	1.33	12.400	14.300		
2024-521	3	ADVIA 120	116 ADVIA-120	17	13.118	0.195	1.48	12.200	14.000		
2024-521	4	AB-CELL DY	115 ABBOTT C-D	41	5.783	0.130	2.26	5.400	6.200		
2024-521	4	AB-CELL DY	153 AB-CEL-RUB	49	5.604	0.104	1.86	5.200	6.000		
2024-521	5	BECTON D	137 B.C DXH	58	6.440	0.072	1.12	6.000	6.900		
2024-521	6	MR Mindray	145 BC-5390	63	5.716	0.106	1.85	5.300	6.100		
2024-521	7	DXH500 Ser	149 BC DXH 500	92	14.541	0.180	1.24	13.500	15.600		
2024-521	8	3 ST	84 ABBOTT C-D	21	18.119	0.390	2.15	16.900	19.400		
2024-521	8	3 ST	138 SY KX-21N	14	18.336	0.282	1.54	17.100	19.600		
2024-522	1	Sysmex CBC	132 SYSMEX XS	125	19.917	0.237	1.19	18.500	21.300		
2024-522	1	Sysmex CBC	141 SYSMEX XN	50	19.960	0.233	1.17	18.600	21.400		
2024-522	1	Sysmex CBC	152 Sysmex XN	214	19.923	0.185	0.93	18.500	21.300		

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-522	2	ACT PENTRA	125 COULTER AC	76	6.328	0.127	2.01	5.900	6.800
2024-522	2	ACT PENTRA	130 ABX PENTRA	29	6.193	0.098	1.58	5.800	6.600
2024-522	3	ADVIA 120	116 ADVIA-120	17	5.612	0.096	1.72	5.200	6.000
2024-522	4	AB-CELL DY	115 ABBOTT C-D	41	17.580	0.314	1.79	16.300	18.800
2024-522	4	AB-CELL DY	153 AB-CEL-RUB	49	17.670	0.344	1.95	16.400	18.900
2024-522	5	BECTON D	137 B.C DXH	58	19.814	0.163	0.82	18.400	21.200
2024-522	6	MR Mindray	145 BC-5390	63	16.875	0.322	1.91	15.700	18.100
2024-522	7	DXH500 Ser	149 BC DXH 500	92	6.292	0.076	1.20	5.900	6.700
2024-522	8	3 ST	84 ABBOTT C-D	21	6.395	0.143	2.24	5.900	6.800
2024-522	8	3 ST	138 SY KX-21N	14	6.264	0.149	2.38	5.800	6.700
551 HEMOGLOBIN (HGB)			CLIA TEST ID #: 795				EVALUATION CRITERIA: TARGET VALUE 7 % OR 2.00 {LOWER}		
2024-523	1	Sysmex CBC	132 SYSMEX XS	125	17.836	0.210	1.18	16.600	19.100
2024-523	1	Sysmex CBC	141 SYSMEX XN	50	17.896	0.168	0.94	16.600	19.100
2024-523	1	Sysmex CBC	152 Sysmex XN	214	17.867	0.151	0.84	16.600	19.100
2024-523	2	ACT PENTRA	125 COULTER AC	76	6.325	0.129	2.04	5.900	6.800
2024-523	2	ACT PENTRA	130 ABX PENTRA	29	6.193	0.094	1.52	5.800	6.600
2024-523	3	ADVIA 120	116 ADVIA-120	17	5.600	0.084	1.50	5.200	6.000
2024-523	4	AB-CELL DY	115 ABBOTT C-D	41	16.603	0.264	1.59	15.400	17.800
2024-523	4	AB-CELL DY	153 AB-CEL-RUB	49	16.767	0.428	2.55	15.600	17.900
2024-523	5	BECTON D	137 B.C DXH	58	17.145	0.165	0.96	15.900	18.300
2024-523	6	MR Mindray	145 BC-5390	63	16.863	0.298	1.77	15.700	18.000
2024-523	7	DXH500 Ser	149 BC DXH 500	92	6.315	0.090	1.42	5.900	6.800
2024-523	8	3 ST	84 ABBOTT C-D	21	18.067	0.464	2.57	16.800	19.300
2024-523	8	3 ST	138 SY KX-21N	14	18.292	0.281	1.54	17.000	19.600
2024-524	1	Sysmex CBC	132 SYSMEX XS	125	6.015	0.102	1.69	5.600	6.400
2024-524	1	Sysmex CBC	141 SYSMEX XN	50	6.092	0.085	1.40	5.700	6.500
2024-524	1	Sysmex CBC	152 Sysmex XN	214	6.099	0.075	1.23	5.700	6.500
2024-524	2	ACT PENTRA	125 COULTER AC	76	15.888	0.167	1.05	14.800	17.000
2024-524	2	ACT PENTRA	130 ABX PENTRA	29	15.910	0.201	1.26	14.800	17.000



**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-524	3	ADVIA 120	116 ADVIA-120	17	17.171	0.343	2.00	16.000	18.400	
2024-524	4	AB-CELL DY	115 ABBOTT C-D	41	5.783	0.123	2.12	5.400	6.200	
2024-524	4	AB-CELL DY	153 AB-CEL-RUB	49	5.606	0.169	3.01	5.200	6.000	
2024-524	5	BECTON D	137 B.C DXH	58	6.442	0.070	1.09	6.000	6.900	
2024-524	6	MR Mindray	145 BC-5390	63	5.721	0.118	2.06	5.300	6.100	
2024-524	7	DXH500 Ser	149 BC DXH 500	92	17.228	0.222	1.29	16.000	18.400	
2024-524	8	3 ST	84 ABBOTT C-D	21	11.890	0.321	2.70	11.100	12.700	
2024-524	8	3 ST	138 SY KX-21N	14	11.854	0.139	1.18	11.000	12.700	
551	HEMOGLOBIN (HGB)		CLIA TEST ID #: 795	EVALUATION CRITERIA: TARGET VALUE 7 % OR 2.00 {LOWER}						
2024-525	1	Sysmex CBC	132 SYSMEX XS	125	13.411	0.177	1.32	12.500	14.400	
2024-525	1	Sysmex CBC	141 SYSMEX XN	50	13.547	0.138	1.02	12.600	14.500	
2024-525	1	Sysmex CBC	152 Sysmex XN	214	13.502	0.129	0.96	12.600	14.400	
2024-525	2	ACT PENTRA	125 COULTER AC	76	13.421	0.153	1.14	12.500	14.400	
2024-525	2	ACT PENTRA	130 ABX PENTRA	29	13.331	0.176	1.32	12.400	14.300	
2024-525	3	ADVIA 120	116 ADVIA-120	17	13.112	0.205	1.57	12.200	14.000	
2024-525	4	AB-CELL DY	115 ABBOTT C-D	41	13.785	0.204	1.48	12.800	14.800	
2024-525	4	AB-CELL DY	153 AB-CEL-RUB	49	13.714	0.254	1.85	12.800	14.700	
2024-525	5	BECTON D	137 B.C DXH	58	11.934	0.140	1.17	11.100	12.800	
2024-525	6	MR Mindray	145 BC-5390	63	13.177	0.233	1.77	12.300	14.100	
2024-525	7	DXH500 Ser	149 BC DXH 500	92	14.397	0.195	1.35	13.400	15.400	
2024-525	8	3 ST	84 ABBOTT C-D	21	6.400	0.163	2.55	6.000	6.800	
2024-525	8	3 ST	138 SY KX-21N	14	6.254	0.139	2.23	5.800	6.700	
552	WHITE CELL COUNT(WBC)		CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE 15 %						
2024-521	1	Sysmex CBC	132 SYSMEX XS	124	3.965	0.142	3.57	3.400	4.600	
2024-521	1	Sysmex CBC	141 SYSMEX XN	50	3.931	0.114	2.90	3.300	4.500	
2024-521	1	Sysmex CBC	152 Sysmex XN	214	3.558	0.130	3.66	3.000	4.100	
2024-521	2	ACT PENTRA	125 COULTER AC	77	8.691	0.243	2.79	7.400	10.000	
2024-521	2	ACT PENTRA	130 ABX PENTRA	29	8.664	0.193	2.23	7.400	10.000	
2024-521	3	ADVIA 120	116 ADVIA-120	17	7.724	0.465	6.02	6.600	8.900	
2024-521	4	AB-CELL DY	115 ABBOTT C-D	42	3.034	0.095	3.14	2.600	3.500	

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-521	4 AB-CELL DY	153 AB-CEL-RUB		48	3.111	0.129	4.15	2.600	3.600		
2024-521	5 BECTON D	137 B.C DXH		58	4.676	0.153	3.28	4.000	5.400		
2024-521	6 MR Mindray	145 BC-5390		63	3.362	0.103	3.06	2.900	3.900		
2024-521	7 DXH500 Ser	149 BC DXH 500		91	6.962	0.183	2.62	5.900	8.000		
2024-521	8 3 ST	84 ABBOTT C-D		21	20.129	1.032	5.13	17.100	23.100		
2024-521	8 3 ST	138 SY KX-21N		14	20.464	0.741	3.62	17.400	23.500		
552	WHITE CELL COUNT(WBC	CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE 15 %								
2024-522	1 Sysmex CBC	132 SYSMEX XS		124	22.883	0.691	3.02	19.500	26.300		
2024-522	1 Sysmex CBC	141 SYSMEX XN		50	23.300	0.444	1.91	19.800	26.800		
2024-522	1 Sysmex CBC	152 Sysmex XN		214	23.041	0.399	1.73	19.600	26.500		
2024-522	2 ACT PENTRA	125 COULTER AC		77	3.003	0.097	3.22	2.600	3.500		
2024-522	2 ACT PENTRA	130 ABX PENTRA		29	3.010	0.106	3.53	2.600	3.500		
2024-522	3 ADVIA 120	116 ADVIA-120		17	3.188	0.118	3.71	2.700	3.700		
2024-522	4 AB-CELL DY	115 ABBOTT C-D		42	9.834	0.237	2.41	8.400	11.300		
2024-522	4 AB-CELL DY	153 AB-CEL-RUB		48	9.798	0.265	2.71	8.300	11.300		
2024-522	5 BECTON D	137 B.C DXH		58	24.955	0.400	1.60	21.200	28.700		
2024-522	6 MR Mindray	145 BC-5390		63	18.392	0.444	2.42	15.600	21.200		
2024-522	7 DXH500 Ser	149 BC DXH 500		91	2.138	0.086	4.03	1.800	2.500		
2024-522	8 3 ST	84 ABBOTT C-D		21	2.971	0.214	7.21	2.500	3.400		
2024-522	8 3 ST	138 SY KX-21N		14	2.879	0.115	3.98	2.400	3.300		
2024-523	1 Sysmex CBC	132 SYSMEX XS		124	21.144	0.634	3.00	18.000	24.300		
2024-523	1 Sysmex CBC	141 SYSMEX XN		50	21.573	0.316	1.47	18.300	24.800		
2024-523	1 Sysmex CBC	152 Sysmex XN		214	21.289	0.372	1.75	18.100	24.500		
2024-523	2 ACT PENTRA	125 COULTER AC		77	2.995	0.098	3.27	2.500	3.400		
2024-523	2 ACT PENTRA	130 ABX PENTRA		29	3.021	0.113	3.73	2.600	3.500		
2024-523	3 ADVIA 120	116 ADVIA-120		17	3.135	0.137	4.37	2.700	3.600		
2024-523	4 AB-CELL DY	115 ABBOTT C-D		42	19.600	0.411	2.10	16.700	22.500		
2024-523	4 AB-CELL DY	153 AB-CEL-RUB		48	19.530	0.623	3.19	16.600	22.500		
2024-523	5 BECTON D	137 B.C DXH		58	21.900	0.374	1.71	18.600	25.200		

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-523	6 MR Mindray	145	BC-5390			63	18.430	0.467	2.54	15.700	21.200
2024-523	7 DXH500 Ser	149	BC DXH 500			91	2.137	0.101	4.74	1.800	2.500
2024-523	8 3 ST	84	ABBOTT C-D			21	19.905	0.863	4.34	16.900	22.900
2024-523	8 3 ST	138	SY KX-21N			14	20.562	0.640	3.11	17.500	23.600
552 WHITE CELL COUNT(WBC)		CLIA TEST ID #: 805		EVALUATION CRITERIA: TARGET VALUE 15 %							
2024-524	1 Sysmex CBC	132	SYSMEX XS			124	3.985	0.132	3.31	3.400	4.600
2024-524	1 Sysmex CBC	141	SYSMEX XN			50	3.919	0.120	3.07	3.300	4.500
2024-524	1 Sysmex CBC	152	Sysmex XN			214	3.567	0.125	3.50	3.000	4.100
2024-524	2 ACT PENTRA	125	COULTER AC			77	19.300	0.520	2.70	16.400	22.200
2024-524	2 ACT PENTRA	130	ABX PENTRA			29	19.386	0.559	2.88	16.500	22.300
2024-524	3 ADVIA 120	116	ADVIA-120			17	17.112	0.740	4.32	14.500	19.700
2024-524	4 AB-CELL DY	115	ABBOTT C-D			42	3.051	0.106	3.48	2.600	3.500
2024-524	4 AB-CELL DY	153	AB-CEL-RUB			48	3.246	0.205	6.32	2.800	3.700
2024-524	5 BECTON D	137	B.C DXH			58	4.703	0.155	3.30	4.000	5.400
2024-524	6 MR Mindray	145	BC-5390			63	3.389	0.116	3.41	2.900	3.900
2024-524	7 DXH500 Ser	149	BC DXH 500			91	17.419	0.332	1.91	14.800	20.000
2024-524	8 3 ST	84	ABBOTT C-D			21	8.100	0.402	4.97	6.900	9.300
2024-524	8 3 ST	138	SY KX-21N			14	8.215	0.179	2.18	7.000	9.400
2024-525	1 Sysmex CBC	132	SYSMEX XS			124	8.295	0.290	3.49	7.100	9.500
2024-525	1 Sysmex CBC	141	SYSMEX XN			50	8.159	0.192	2.35	6.900	9.400
2024-525	1 Sysmex CBC	152	Sysmex XN			214	7.799	0.177	2.27	6.600	9.000
2024-525	2 ACT PENTRA	125	COULTER AC			77	8.676	0.221	2.55	7.400	10.000
2024-525	2 ACT PENTRA	130	ABX PENTRA			29	8.700	0.228	2.62	7.400	10.000
2024-525	3 ADVIA 120	116	ADVIA-120			17	7.747	0.530	6.85	6.600	8.900
2024-525	4 AB-CELL DY	115	ABBOTT C-D			42	7.510	0.170	2.27	6.400	8.600
2024-525	4 AB-CELL DY	153	AB-CEL-RUB			48	7.417	0.318	4.28	6.300	8.500
2024-525	5 BECTON D	137	B.C DXH			58	9.789	0.171	1.75	8.300	11.300
2024-525	6 MR Mindray	145	BC-5390			63	8.163	0.210	2.58	6.900	9.400
2024-525	7 DXH500 Ser	149	BC DXH 500			91	6.910	0.163	2.36	5.900	7.900

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW							
ANALYTE											
SAMPLE	METHOD	SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-525	8 3 ST	84	ABBOTT C-D		21	2.929	0.167	5.69	2.500	3.400	
2024-525	8 3 ST	138	SY KX-21N		14	2.892	0.100	3.45	2.500	3.300	

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 134 PLATELET COUNT NEW							
ANALYTE											
SAMPLE	METHOD	SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
553 PLATELET COUNT		CLIA TEST ID #: 815		EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-521	1 SYSMEX CBC	79	SYSMEX XS		123	52.802	3.322	6.29	40.000	66.000	
2024-521	1 SYSMEX CBC	87	SYSMEX XN		51	45.569	2.584	5.67	34.000	57.000	
2024-521	1 SYSMEX CBC	98	SYSMEX 350		215	46.930	3.092	6.59	35.000	59.000	
2024-521	2 ACT5 PENTR	73	COULTER AC		75	237.365	10.112	4.26	178.000	297.000	
2024-521	2 ACT5 PENTR	78	ABX PENTRA		29	234.103	7.770	3.32	176.000	293.000	
2024-521	3 ADVIA 120	64	ADVIA-120		17	240.235	25.522	10.62	180.000	300.000	
2024-521	4 AB- CELL-D	63	ABBOTT C-D		40	81.375	5.448	6.70	61.000	102.000	
2024-521	4 AB- CELL-D	100	ABB.RUBY		48	79.702	9.837	12.34	60.000	100.000	
2024-521	5 BECTON D	83	B.C600,800		58	84.776	3.146	3.71	64.000	106.000	
2024-521	6 MR Mindray	91	BC-5390		63	47.032	2.731	5.81	35.000	59.000	
2024-521	8 3 ST	31	ABBOTT C-D		21	376.714	39.794	10.56	283.000	471.000	
2024-521	8 3 ST	84	KX21,300		14	407.286	39.191	9.62	305.000	509.000	
2024-521	10 DxH	94	BC DXH 500		92	243.033	11.750	4.83	182.000	304.000	
2024-522	1 SYSMEX CBC	79	SYSMEX XS		123	396.133	17.093	4.31	297.000	495.000	
2024-522	1 SYSMEX CBC	87	SYSMEX XN		51	429.740	10.710	2.49	322.000	537.000	
2024-522	1 SYSMEX CBC	98	SYSMEX 350		215	428.929	16.249	3.79	322.000	536.000	
2024-522	2 ACT5 PENTR	73	COULTER AC		75	74.400	5.274	7.09	56.000	93.000	
2024-522	2 ACT5 PENTR	78	ABX PENTRA		29	72.241	3.812	5.28	54.000	90.000	
2024-522	3 ADVIA 120	64	ADVIA-120		17	51.588	5.489	10.64	39.000	64.000	
2024-522	4 AB- CELL-D	63	ABBOTT C-D		40	148.590	12.036	8.10	111.000	186.000	
2024-522	4 AB- CELL-D	100	ABB.RUBY		48	141.370	45.216	31.98	106.000	177.000	

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 134 PLATELET COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST		REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-522	5	BECTON D	83	B.C600,800	58	491.368	19.815	4.03	369.000	614.000	
2024-522	6	MR Mindray	91	BC-5390	63	602.806	12.975	2.15	452.000	754.000	
2024-522	8	3 ST	31	ABBOTT C-D	21	63.762	5.797	9.09	48.000	80.000	
2024-522	8	3 ST	84	KX21,300	14	65.714	6.797	10.34	49.000	82.000	
2024-522	10	DxH	94	BC DXH 500	92	76.087	6.148	8.08	57.000	95.000	
553	PLATELET COUNT	CLIA TEST ID #: 815		EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-523	1	SYSMEX CBC	79	SYSMEX XS	123	401.074	17.294	4.31	301.000	501.000	
2024-523	1	SYSMEX CBC	87	SYSMEX XN	51	429.588	10.496	2.44	322.000	537.000	
2024-523	1	SYSMEX CBC	98	SYSMEX 350	215	427.400	14.695	3.44	321.000	534.000	
2024-523	2	ACT5 PENTR	73	COULTER AC	75	73.867	5.270	7.13	55.000	92.000	
2024-523	2	ACT5 PENTR	78	ABX PENTRA	29	72.897	4.521	6.20	55.000	91.000	
2024-523	3	ADVIA 120	64	ADVIA-120	17	51.529	6.223	12.08	39.000	64.000	
2024-523	4	AB- CELL-D	63	ABBOTT C-D	40	492.000	23.373	4.75	369.000	615.000	
2024-523	4	AB- CELL-D	100	ABB.RUBY	48	494.413	33.682	6.81	371.000	618.000	
2024-523	5	BECTON D	83	B.C600,800	58	488.034	14.192	2.91	366.000	610.000	
2024-523	6	MR Mindray	91	BC-5390	63	605.254	15.881	2.62	454.000	757.000	
2024-523	8	3 ST	31	ABBOTT C-D	21	372.190	46.868	12.59	279.000	465.000	
2024-523	8	3 ST	84	KX21,300	14	400.692	33.899	8.46	301.000	501.000	
2024-523	10	DxH	94	BC DXH 500	92	76.261	5.503	7.22	57.000	95.000	
2024-524	1	SYSMEX CBC	79	SYSMEX XS	123	52.744	3.376	6.40	40.000	66.000	
2024-524	1	SYSMEX CBC	87	SYSMEX XN	51	45.000	2.815	6.25	34.000	56.000	
2024-524	1	SYSMEX CBC	98	SYSMEX 350	215	46.545	3.132	6.73	35.000	58.000	
2024-524	2	ACT5 PENTR	73	COULTER AC	75	467.320	18.780	4.02	350.000	584.000	
2024-524	2	ACT5 PENTR	78	ABX PENTRA	29	463.103	11.034	2.38	347.000	579.000	
2024-524	3	ADVIA 120	64	ADVIA-120	17	489.235	37.370	7.64	367.000	612.000	
2024-524	4	AB- CELL-D	63	ABBOTT C-D	40	82.150	5.543	6.75	62.000	103.000	
2024-524	4	AB- CELL-D	100	ABB.RUBY	48	78.894	6.099	7.73	59.000	99.000	
2024-524	5	BECTON D	83	B.C600,800	58	84.069	3.134	3.73	63.000	105.000	
2024-524	6	MR Mindray	91	BC-5390	63	47.403	2.848	6.01	36.000	59.000	

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 134 PLATELET COUNT NEW							
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024-524	8 3 ST	31 ABBOTT C-D		21	191.714	19.199	10.01	144.000	240.000		
2024-524	8 3 ST	84 KX21,300		14	208.846	17.589	8.42	157.000	261.000		
2024-524	10 DxH	94 BC DXH 500		92	473.065	17.915	3.79	355.000	591.000		
553 PLATELET COUNT		CLIA TEST ID #: 815		EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-525	1 SYSMEX CBC	79 SYSMEX XS		123	207.603	9.628	4.64	156.000	260.000		
2024-525	1 SYSMEX CBC	87 SYSMEX XN		51	211.549	6.599	3.12	159.000	264.000		
2024-525	1 SYSMEX CBC	98 SYSMEX 350		215	212.090	7.790	3.67	159.000	265.000		
2024-525	2 ACT5 PENTR	73 COULTER AC		75	235.851	8.857	3.76	177.000	295.000		
2024-525	2 ACT5 PENTR	78 ABX PENTRA		29	231.000	7.670	3.32	173.000	289.000		
2024-525	3 ADVIA 120	64 ADVIA-120		17	237.294	22.785	9.60	178.000	297.000		
2024-525	4 AB- CELL-D	63 ABBOTT C-D		40	280.225	15.850	5.66	210.000	350.000		
2024-525	4 AB- CELL-D	100 ABB.RUBY		48	270.646	23.173	8.56	203.000	338.000		
2024-525	5 BECTON D	83 B.C600,800		58	276.754	10.328	3.73	208.000	346.000		
2024-525	6 MR Mindray	91 BC-5390		63	265.397	6.536	2.46	199.000	332.000		
2024-525	8 3 ST	31 ABBOTT C-D		21	61.476	5.342	8.69	46.000	77.000		
2024-525	8 3 ST	84 KX21,300		14	66.154	3.301	4.99	50.000	83.000		
2024-525	10 DxH	94 BC DXH 500		92	243.187	11.145	4.58	182.000	304.000		

SPEC: 20 HEMATOLOGY		SUB: 75 BODY FLUID		GRP: 145 BODY FLUID CELL COU.							
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
159 BF RED CELL COUNT		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {GREATER}							
2024-561				39	0.684	0.831	121.38	0	3.000		
2024-562				39	1055.256	107.381	10.18	733.000	1377.000		

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPEC: 20 HEMATOLOGY                      SUB: 75 BODY FLUID                      GRP: 145 BODY FLUID CELL COU.

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
159	BF RED CELL COUNT	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {GREATER}							
	2024-563				39	1052.184	74.066	7.04	789.000	1315.000
	2024-564				39	0.667	0.915	137.28	0	3.000
	2024-565				39	0.351	0.580	164.98	0	2.000
160	BF WHITE CELL COUNT									
	2024-561				38	4.553	2.022	44.42	0	11.000
	2024-562				38	257.514	33.660	13.07	157.000	358.000
	2024-563				38	262.757	30.786	11.72	170.000	355.000
	2024-564				38	3.816	1.684	44.12	0	9.000
	2024-565				38	4.211	1.575	37.42	0	9.000

**Participant Summary**  
**MONTH 6 OF YEAR 2024**

SPE: 30 IMMUNOHEMATOLOGY		SUB: 80 ABO-RH				GRP: 150 ABO-RH							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
083 ABO GROUP													
2024-571				001 003	001 003		002 - A1	77	2	77	100		
2024-571				001 003	001 003		001 - A	77	75	77	100		
2024-572				004 004	004 004		004 - B	77	77	77	100		
2024-573				001 003	001 003		001 - A	77	75	77	100		
2024-573				001 003	001 003		002 - A1	77	2	77	100		
2024-574				008 008	008 008		008 - O	77	77	77	100		
2024-575				008 008	008 008		008 - O	77	77	77	100		
126 RH TYPE													
2024-571				001 003	001 003		001 - Rh+	77	77	77	100		
2024-572				001 003	001 003		001 - Rh+	77	77	77	100		
2024-573				003 004	003 004		004 - Rh-	77	68	77	100		
2024-573				003 004	003 004		003 - Rh-Du np	77	9	77	100		
2024-574				001 003	001 003		001 - Rh+	77	77	77	100		
2024-575				003 004	003 004		004 - Rh-	77	68	77	100		
2024-575				003 004	003 004		003 - Rh-Du np	77	9	77	100		



**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 160 Indirect COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
084 INDIRECT COOMBS											
2024-581				002 002	002 002		002 - POSITIVE	62	62	62	100
2024-582				001 001	001 001		001 - NEGATIVE	62	62	62	100
2024-583				002 002	002 002		001 - NEGATIVE	62	1	61	0
2024-583				002 002	002 002		002 - POSITIVE	62	61	61	100
2024-584				001 001	001 001		001 - NEGATIVE	62	62	62	100
2024-585				001 001	001 001		001 - NEGATIVE	62	61	61	100
2024-585				001 001	001 001		002 - POSITIVE	62	1	61	0
SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 165 Direct COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
179 DIRECT ANTIG(COOMBS)											
2024-291	001 Poly AHG	001 Gel			002 004		004 - 4+	15	6	15	100
2024-291	001 Poly AHG	001 Gel			002 004		003 - 3+	15	8	15	100
2024-291	001 Poly AHG	001 Gel			002 004		002 - 2+	15	1	15	100
2024-291	001 Poly AHG	002 Tubo				002 004	004 - 4+	32	2	32	100
2024-291	001 Poly AHG	002 Tubo				002 004	003 - 3+	32	8	32	100
2024-291	001 Poly AHG	002 Tubo				002 004	002 - 2+	32	22	32	100
2024-291	002 MnoAnt-IgG	001 Gel			002 004		003 - 3+	13	7	13	100
2024-291	002 MnoAnt-IgG	001 Gel			002 004		004 - 4+	13	6	13	100
2024-291	002 MnoAnt-IgG	002 Tubo			002 004		003 - 3+	14	5	14	100
2024-291	002 MnoAnt-IgG	002 Tubo			002 004		002 - 2+	14	9	14	100

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 165 Direct COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
179 DIRECT ANTIG(COOMBS)											
2024-292	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	15	15	15	100
2024-292	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	32	32	32	100
2024-292	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	13	13	13	100
2024-292	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	14	14	14	100
2024-293	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	15	15	15	100
2024-293	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	32	32	32	100
2024-293	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	13	13	13	100
2024-293	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	14	14	14	100
2024-294	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	15	15	15	100
2024-294	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	32	32	32	100
2024-294	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	13	13	13	100
2024-294	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	14	14	14	100
2024-295	001 Poly AHG	001 Gel			002 004		003 - 3+	15	9	15	100
2024-295	001 Poly AHG	001 Gel			002 004		004 - 4+	15	6	15	100
2024-295	001 Poly AHG	002 Tubo				002 004	004 - 4+	32	1	31	100
2024-295	001 Poly AHG	002 Tubo				002 004	001 - Negativo	32	1	31	0
2024-295	001 Poly AHG	002 Tubo				002 004	003 - 3+	32	7	31	100
2024-295	001 Poly AHG	002 Tubo				002 004	002 - 2+	32	23	31	100
2024-295	002 MnoAnt-IgG	001 Gel			002 004		003 - 3+	13	8	13	100
2024-295	002 MnoAnt-IgG	001 Gel			002 004		004 - 4+	13	5	13	100
2024-295	002 MnoAnt-IgG	002 Tubo			002 004		002 - 2+	14	10	14	100
2024-295	002 MnoAnt-IgG	002 Tubo			002 004		003 - 3+	14	4	14	100

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPE: 30 IMMUNOHEMATOLOGY												SUB: 100 COMPATIBILITY TESTING				GRP: 170 COMPATIBILITY TEST.					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score										
085 COMPATIBIL. TESTING																					
2024-591				002 002	002 002		002 - INCOMPATIB	39	39	39	100										
2024-592				001 001	001 001		001 - COMPATIBLE	39	39	39	100										
2024-593				002 002	002 002		002 - INCOMPATIB	39	39	39	100										
2024-594				001 001	001 001		001 - COMPATIBLE	39	39	39	100										
2024-595				001 001	001 001		001 - COMPATIBLE	39	39	39	100										

**Participant Summary**

**MONTH 6 OF YEAR 2024**

SPE: 30 IMMUNOHEMATOLOGY		SUB: 110 ANTIBODY IDENTIFICATION				GRP: 180 ANTIBODY IDENT.					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART # LABS	# LABS ANSW	# "SF" LABS	Score
086 ANTIBODY IDENT.TEST.											
2024-591				016 016	016 016		016 - Anti K	20	10	20	100
2024-591				018 018	018 018		018 - Anti Fy a	20	10	20	100
2024-592				001 001	001 001		001 - UN. ANT.ND	10	10	10	100
2024-593				007 007	007 007		007 - Anti E	10	10	10	100
2024-594				001 001	001 001		001 - UN. ANT.ND	10	10	10	100
2024-595				001 001	001 001		001 - UN. ANT.ND	10	10	10	100